Literature DB >> 27668238

Treatment strategies of epidermal growth factor receptor inhibitor-induced skin toxicities: pre-emptive or reactive?

Yung-Tsu Cho1, Kai-Lung Chen1, Chia-Yu Chu1.   

Abstract

Entities:  

Year:  2016        PMID： 27668238      PMCID： PMC5009022          DOI： 10.21037/atm.2016.08.03

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  12 in total

1.  Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer.

Authors:  Kai-Lung Chen; Chia-Chi Lin; Yung-Tsu Cho; Che-Wen Yang; Yi-Shuan Sheen; Hsiao-En Tsai; Chia-Yu Chu
Journal:  JAMA Dermatol       Date:  2016-03       Impact factor: 10.282

2.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

Review 3.  Tetracyclines: nonantibiotic properties and their clinical implications.

Authors:  Allen N Sapadin; Raul Fleischmajer
Journal:  J Am Acad Dermatol       Date:  2006-02       Impact factor: 11.527

4.  Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis.

Authors:  Yuxia Jia; Mario E Lacouture; Xiao Su; Shenhong Wu
Journal:  J Support Oncol       Date:  2009 Nov-Dec

5.  Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.

Authors:  Mario E Lacouture; Edith P Mitchell; Bilal Piperdi; Madhavan V Pillai; Heather Shearer; Nicholas Iannotti; Feng Xu; Mohamed Yassine
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

Review 6.  Mechanisms of cutaneous toxicities to EGFR inhibitors.

Authors:  Mario E Lacouture
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

Review 7.  ERBB receptors and cancer: the complexity of targeted inhibitors.

Authors:  Nancy E Hynes; Heidi A Lane
Journal:  Nat Rev Cancer       Date:  2005-05       Impact factor: 60.716

8.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Authors:  Caicun Zhou; Yi-Long Wu; Gongyan Chen; Jifeng Feng; Xiao-Qing Liu; Changli Wang; Shucai Zhang; Jie Wang; Songwen Zhou; Shengxiang Ren; Shun Lu; Li Zhang; Chengping Hu; Chunhong Hu; Yi Luo; Lei Chen; Ming Ye; Jianan Huang; Xiuyi Zhi; Yiping Zhang; Qingyu Xiu; Jun Ma; Li Zhang; Changxuan You
Journal:  Lancet Oncol       Date:  2011-07-23       Impact factor: 41.316

9.  Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.

Authors:  Barbara Melosky; Helen Anderson; Ronald L Burkes; Quincy Chu; Desiree Hao; Vincent Ho; Cheryl Ho; Wendy Lam; Christopher W Lee; Natasha B Leighl; Nevin Murray; Sophie Sun; Robert Winston; Janessa J Laskin
Journal:  J Clin Oncol       Date:  2015-11-16       Impact factor: 44.544

10.  Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.

Authors:  Alon Scope; Anna Liza C Agero; Stephen W Dusza; Patricia L Myskowski; Jocelyn A Lieb; Leonard Saltz; Nancy E Kemeny; Allan C Halpern
Journal:  J Clin Oncol       Date:  2007-12-01       Impact factor: 44.544
View more
  2 in total

1.  Cutaneous Toxicities of Molecular Targeted Therapies.

Authors:  Dana Lucia Stanculeanu; Daniela Zob; Oana Catalina Toma; Bogdan Georgescu; Laura Papagheorghe; Raluca Ioana Mihaila
Journal:  Maedica (Bucur)       Date:  2017-01

Review 2.  Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.

Authors:  Chia-Yu Chu; Jennifer Choi; Beth Eaby-Sandy; Corey J Langer; Mario E Lacouture
Journal:  Oncologist       Date:  2018-04-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.